Endonovo Therapeutics, Inc. (ENDV)
OTCMKTS
· Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
Apr 25, 2025, 11:55 AM EDT
Endonovo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2013 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2013 - 2017 |
| Revenue | 0.26 | 0.14 | 0.07 | 0.17 | 0.31 | 0.08 | Upgrade
|
| Revenue Growth (YoY) | 1699.85% | 85.15% | -55.91% | -46.55% | 272.51% | - | Upgrade
|
| Cost of Revenue | 0.01 | 0.01 | 0.01 | 0.07 | 0.09 | 0.01 | Upgrade
|
| Gross Profit | 0.25 | 0.13 | 0.06 | 0.1 | 0.22 | 0.07 | Upgrade
|
| Selling, General & Admin | 2.86 | 3.39 | 2.28 | 2.36 | 3.22 | 3.31 | Upgrade
|
| Research & Development | - | - | - | 0 | 0.15 | 0.27 | Upgrade
|
| Operating Expenses | 2.86 | 3.39 | 2.28 | 3.01 | 4.03 | 4.23 | Upgrade
|
| Operating Income | -2.62 | -3.26 | -2.23 | -2.91 | -3.81 | -4.16 | Upgrade
|
| Interest Expense | -1.22 | -1.32 | -0.94 | -2.08 | -6.09 | -5.2 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.73 | -14.25 | 0.04 | 5.16 | -7.49 | 2.6 | Upgrade
|
| EBT Excluding Unusual Items | -4.56 | -18.84 | -3.13 | 0.16 | -17.39 | -6.75 | Upgrade
|
| Other Unusual Items | 0.16 | 0.36 | 0.02 | -0.56 | 0.07 | 0.32 | Upgrade
|
| Pretax Income | -4.4 | -18.47 | -3.1 | -0.4 | -17.31 | -6.44 | Upgrade
|
| Earnings From Continuing Operations | -4.4 | -18.47 | -3.1 | -0.4 | -17.31 | -6.44 | Upgrade
|
| Net Income | -4.4 | -18.47 | -3.1 | -0.4 | -17.31 | -6.44 | Upgrade
|
| Net Income to Common | -4.4 | -18.47 | -3.1 | -0.4 | -17.31 | -6.44 | Upgrade
|
| Shares Outstanding (Basic) | 255 | 139 | 60 | 12 | 1 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 255 | 139 | 60 | 12 | 1 | 0 | Upgrade
|
| Shares Change (YoY) | 130.88% | 132.64% | 389.83% | 1651.87% | 92.38% | 49.72% | Upgrade
|
| EPS (Basic) | -0.02 | -0.13 | -0.05 | -0.03 | -24.83 | -17.76 | Upgrade
|
| EPS (Diluted) | -0.06 | -0.13 | -0.05 | -0.03 | -24.83 | -17.76 | Upgrade
|
| Free Cash Flow | -0.63 | -0.68 | -0.99 | -0.74 | -2.54 | -2.89 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.02 | -0.06 | -3.65 | -7.97 | Upgrade
|
| Gross Margin | 96.21% | 92.62% | 79.50% | 60.57% | 69.89% | 84.47% | Upgrade
|
| Operating Margin | -1023.16% | -2411.69% | -3045.68% | -1756.49% | -1228.08% | -4995.33% | Upgrade
|
| Profit Margin | -1722.23% | -13649.17% | -4247.17% | -238.60% | -5582.37% | -7729.53% | Upgrade
|
| Free Cash Flow Margin | -246.32% | -501.52% | -1349.54% | -447.29% | -820.08% | -3468.29% | Upgrade
|
| EBITDA | -1.97 | -2.62 | -1.58 | -2.26 | -3.16 | -3.51 | Upgrade
|
| D&A For EBITDA | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | 0.65 | Upgrade
|
| EBIT | -2.62 | -3.26 | -2.23 | -2.91 | -3.81 | -4.16 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.